Nanomaterial Application in Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 October 2025 | Viewed by 43
Special Issue Editors
2. California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA
Interests: nanomaterial; nanotherapeutics, adjuvant; vaccine; immune modulation; tolerogenic vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The immune system plays a crucial role in both defending the body against pathogens and maintaining tolerance to self-antigens. However, the delicate balance between enhancing and suppressing immune responses can be disrupted in various diseases, including cancer, infections, allergies, and autoimmune disorders. In this context, immune modulation through the use of nanomaterials in vaccines represents an exciting frontier for therapeutic development.
This Special Issue seeks to highlight research on nanomaterial-based vaccines that either enhance immune responses—such as those targeting cancer and infectious diseases—or suppress them, as seen in vaccines aimed at treating autoimmune diseases and allergies. Contributions may include studies on vaccine design, nanoparticle technologies, and tolerogenic vaccines that help regulate immune responses in a controlled manner. By advancing our understanding of these innovative strategies, we aim to foster the development of vaccines that both boost immunity and modulate it to prevent unwanted immune activation.
Prof. Dr. Tian Xia
Prof. Dr. Bingbing Sun
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterials
- vaccine delivery
- immunogenicity enhancement
- tolerogenic nanovaccine
- nanotechnology
- vaccine stability
- vaccine design
- nanoparticles
- immunization strategies
- biotechnology in vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
